{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Holstein SA"],"funding":["Janssen Biotech","Bristol-Myers Squibb","Celgene","Amgen","Takeda Pharmaceutical Company","NHLBI NIH HHS","National Heart, Lung, and Blood Institute","National Cancer Institute","NCI NIH HHS","National Institutes of Health","Sanofi","Novartis"],"pagination":["e7-e15"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6942175"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(1)"],"pubmed_abstract":["The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice."],"journal":["Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation"],"pubmed_title":["Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling."],"pmcid":["PMC6942175"],"funding_grant_id":["UG1 HL069286","U24 HL138660","R01 HL107213","U10 HL069294","U24 CA076518","UG1 HL069249","R01HL107213","U01 HL069294"],"pubmed_authors":["McCarthy PL","Costa LJ","Stadtmauer EA","Waldvogel SL","Shi Q","Hari P","Pasquini MC","Munshi NC","Hahn T","Jacob A","Holstein SA","Al-Kadhimi Z","Hillengass J","Oliva S"],"additional_accession":[]},"is_claimable":false,"name":"Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.","description":"The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jan","modification":"2024-12-03T23:17:37.181Z","creation":"2021-02-20T17:13:55Z"},"accession":"S-EPMC6942175","cross_references":{"pubmed":["31526843"],"doi":["10.1016/j.bbmt.2019.09.015"]}}